4985S-10: C80702 colon

CTSU C80702: A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer

Type of Study
Cancer (Oncology) - Colon
Location
Swedish Cancer Institute
Short Description

Purpose: This randomized phase III trial is studying giving oxaliplatin, leucovorin calcium, and fluorouracil together to compare how well they work when given together with or without celecoxib in treating patients with stage III colon cancer previously treated with surgery.

Read and print the C80702_Patient_Guide

 

 

Status
Open to Enrollment
Principal Investigator
Gary Goodman, M.D.
Eligibility Notes
  • Histologically confirmed adenocarcinoma of the colon
  • Stage III disease
  • Gross inferior (caudal) margin of the primary tumor must be >= 12 cm from the anal verge
    • No rectal cancer
  • Synchronous colon cancers allowed
    • No synchronous colon and rectal primary tumors
  • Completely resected tumor
  • No evidence of residual involved lymph node disease or metastatic disease
  • No neurosensory or neuromotor toxicity >= grade 2
  • No known allergy to platinum compounds
  • No prior allergic reaction or hypersensitivity to sulfonamide, celecoxib, or NSAIDs
  • No history of upper gastrointestinal ulceration, bleeding, or perforation within the past 3 years
More Info Link
Additional information about the study summary and eligibility criteria may be viewed on the U.S. National Institutes of Health (NIH) website.
Phone
(206) 215-3086
Email
CancerResearch@swedish.org